Looking forward, looking back.
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003657:Decision Making; D017277:Drug Approval / Q000458:organization & administration*; D005060:Europe; D033161:Government Regulation; D006801:Humans; D000077544:Panitumumab; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D000077544:Panitumumab